All In Biotech

Drug Trial Radar · NCT05407246

Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study on the Efficacy and Safety of hemay005 Tablets in the Treatment of Active Ankylosing Spondylitis

Last checked: Nov 19, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

90

Actual

Start

Aug 5, 2022

Primary completion

Aug 18, 2023

Study completion Aug 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jun 7, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled phase II clinical study. The study was divided into three stages, including screening period(4-week), treatment period(16-week) and observation period. All subjects need to enter a 28 day (4-week) observation period after stopping hemay005 treatment. Main purpose: The efficacy of hemay005 tablet in the treatment of active ankylosing spondylitis (as) was evaluated by placebo parallel control. Secondary purpose: * To evaluate the safety of oral hemay005 tablets in patients with active as. * To evaluate the population pharmacokinetics of hemay005 tablets in patients with active as.

Conditions

  • Active Ankylosing Spondylitis

Interventions

  • Hemay005Drug

    Hemay005 60 mg treatment group (group A): hemay005 tablets 60 mg bid were used during the treatment period; Hemay005 75 mg treatment group (group B): hemay005 75 mg bid was used during the treatment period; Placebo group (Group C): placebo (hemay005 tablet simulant) bid was used during the treatment period;

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ASAS20Time frame: week 16

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Bengbu Medical University

    Hefei, Anhui, China

  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The Third Affiliated Hospital of Sun Yat sen University

    Guangzhou, Guangdong, China

  • Hebei CNPC Central Hospital

    Langfang, Hebei, China

  • Puyang Oilfield General Hospital

    Puyang, Henan, China

  • Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of science and technology

    Wuhan, Hubei, China

  • Chenzhou first people's Hospital

    Chenzhou, Hunan, China

  • Pingxiang people's Hospital

    Pingxiang, Jiangxi, China

  • Jilin Provincial People's Hospital

    Changchun, Jilin, China

  • The First Affiliated Hospital of Medical College of Xi'an Jiaotong University

    Xi’an, Shanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.